- Home
- STDN vs HRMY Comparison
STDN vs HRMY Comparison
Compare STDN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STDN | HRMY |
|---|---|---|
| Founded | N/A | 2017 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | STDN | HRMY |
|---|---|---|
| Price | $16.56 | $41.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $44.11 |
| AVG Volume (30 Days) | ★ 766.0K | 681.8K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 1.84 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | N/A | $19.75 |
| Revenue Next Year | N/A | $12.88 |
| P/E Ratio | ★ N/A | $21.40 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $7.05 | $25.52 |
| 52 Week High | $16.22 | $40.87 |
Technical Indicators
Market Signals| Indicator | STDN | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 71.11 | 64.01 |
| Support Level | $11.50 | $37.30 |
| Resistance Level | N/A | $40.87 |
| Average True Range (ATR) | 1.37 | 1.17 |
| MACD | 0.40 | 0.04 |
| Stochastic Oscillator | 89.22 | 90.02 |
Price Performance
Historical ComparisonAbout STDN Standard Nuclear Inc. Class A Common Stock
Standard Nuclear Inc is an independent advanced nuclear fuel company. The company designs, engineers, and manufactures advanced nuclear fuels, with a primary focus on TRISO fuel for advanced reactors. Its operations include industrial-scale TRISO fuel manufacturing and the development of fuel for advanced reactors that utilize TRISO fuel. The company operates in a single operating and reportable segment, as it is engaged in a single business activity of TRISO production. It derives revenue from fuel development and services agreements. Geographically, the maximum revenue is generated from the United States.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.